Gilead Grabs Cicletanine For PAH From Navitas
This article was originally published in The Pink Sheet Daily
Executive Summary
Bargain-priced drug has orphan status pending, could complement Letairis.
You may also be interested in...
Actelion Adds to PAH Franchise with IV drug from GeneraMedix
Buying GeneraMedix’s IV formulation of epoprostenol allows Actelion to leverage its infrastructure and experience in PAH and strengthen its lead in this increasingly crowded market.
Actelion Adds to PAH Franchise with IV drug from GeneraMedix
Buying GeneraMedix’s IV formulation of epoprostenol allows Actelion to leverage its infrastructure and experience in PAH and strengthen its lead in this increasingly crowded market.
Gilead Boasts Vibrant Pipeline; Boosts R&D Spend Guidance
Biotech reports continuing increases in sales of its HIV combination drugs during second-quarter earnings call.